JP2021503010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503010A5 JP2021503010A5 JP2020544727A JP2020544727A JP2021503010A5 JP 2021503010 A5 JP2021503010 A5 JP 2021503010A5 JP 2020544727 A JP2020544727 A JP 2020544727A JP 2020544727 A JP2020544727 A JP 2020544727A JP 2021503010 A5 JP2021503010 A5 JP 2021503010A5
- Authority
- JP
- Japan
- Prior art keywords
- absence
- epilepsy
- seizure
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010010904 Convulsion Diseases 0.000 claims 23
- 208000028311 absence seizure Diseases 0.000 claims 23
- 206010034759 Petit mal epilepsy Diseases 0.000 claims 18
- 208000003554 absence epilepsy Diseases 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 9
- -1 carbamate compound Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 206010015037 epilepsy Diseases 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamic acid group Chemical group C(N)(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 5
- 230000007812 deficiency Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000006731 (C1-C8) thioalkoxy group Chemical group 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 3
- 201000001913 Childhood absence epilepsy Diseases 0.000 claims 3
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 3
- 201000008189 Juvenile absence epilepsy Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004494 ethyl ester group Chemical group 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 210000000744 eyelid Anatomy 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 3
- 230000000366 juvenile effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000537 electroencephalography Methods 0.000 claims 1
- 238000010304 firing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023061633A JP7578747B2 (ja) | 2017-11-14 | 2023-04-05 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170151248 | 2017-11-14 | ||
| KR10-2017-0151248 | 2017-11-14 | ||
| PCT/KR2018/013761 WO2019098628A1 (ko) | 2017-11-14 | 2018-11-13 | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061633A Division JP7578747B2 (ja) | 2017-11-14 | 2023-04-05 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503010A JP2021503010A (ja) | 2021-02-04 |
| JP2021503010A5 true JP2021503010A5 (enExample) | 2021-12-23 |
| JP7258901B2 JP7258901B2 (ja) | 2023-04-17 |
Family
ID=66540315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544727A Active JP7258901B2 (ja) | 2017-11-14 | 2018-11-13 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
| JP2023061633A Active JP7578747B2 (ja) | 2017-11-14 | 2023-04-05 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061633A Active JP7578747B2 (ja) | 2017-11-14 | 2023-04-05 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200352907A1 (enExample) |
| EP (1) | EP3711758B1 (enExample) |
| JP (2) | JP7258901B2 (enExample) |
| KR (1) | KR102739584B1 (enExample) |
| CN (1) | CN111432812A (enExample) |
| AU (1) | AU2018367729B2 (enExample) |
| BR (1) | BR112020009265A2 (enExample) |
| CA (1) | CA3081223A1 (enExample) |
| DK (1) | DK3711758T3 (enExample) |
| ES (1) | ES2982316T3 (enExample) |
| FI (1) | FI3711758T3 (enExample) |
| IL (1) | IL274428B2 (enExample) |
| MX (1) | MX2020004972A (enExample) |
| PL (1) | PL3711758T3 (enExample) |
| PT (1) | PT3711758T (enExample) |
| WO (1) | WO2019098628A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113052A1 (en) * | 2018-09-21 | 2020-03-26 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus |
| CN116143717B (zh) * | 2021-11-22 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 一种氘代氨基甲酸酯化合物及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6383764B1 (en) | 2000-04-28 | 2002-05-07 | The Regents Of The University Of California | Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP) |
| KR100534556B1 (ko) | 2001-10-26 | 2005-12-08 | 주식회사 오리엔트바이오 | 알파１ｇ 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
| EP1707204A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US8501436B2 (en) * | 2009-06-22 | 2013-08-06 | Sk Biopharmaceuticals Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9629853B2 (en) | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| KR102489052B1 (ko) | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| DK3556349T3 (da) | 2016-12-14 | 2022-01-03 | Sk Biopharmaceuticals Co Ltd | Parenteralt flydende præparat omfattende en carbamatforbindelse |
| CA3073925A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | Treatment of cns conditions |
-
2018
- 2018-11-13 JP JP2020544727A patent/JP7258901B2/ja active Active
- 2018-11-13 MX MX2020004972A patent/MX2020004972A/es unknown
- 2018-11-13 AU AU2018367729A patent/AU2018367729B2/en active Active
- 2018-11-13 ES ES18878222T patent/ES2982316T3/es active Active
- 2018-11-13 KR KR1020207013843A patent/KR102739584B1/ko active Active
- 2018-11-13 DK DK18878222.1T patent/DK3711758T3/da active
- 2018-11-13 US US16/763,636 patent/US20200352907A1/en active Pending
- 2018-11-13 EP EP18878222.1A patent/EP3711758B1/en active Active
- 2018-11-13 WO PCT/KR2018/013761 patent/WO2019098628A1/ko not_active Ceased
- 2018-11-13 PT PT188782221T patent/PT3711758T/pt unknown
- 2018-11-13 CN CN201880073833.7A patent/CN111432812A/zh active Pending
- 2018-11-13 CA CA3081223A patent/CA3081223A1/en active Pending
- 2018-11-13 PL PL18878222.1T patent/PL3711758T3/pl unknown
- 2018-11-13 BR BR112020009265-7A patent/BR112020009265A2/pt unknown
- 2018-11-13 FI FIEP18878222.1T patent/FI3711758T3/fi active
-
2020
- 2020-05-04 IL IL274428A patent/IL274428B2/en unknown
-
2023
- 2023-04-05 JP JP2023061633A patent/JP7578747B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2016512531A5 (enExample) | ||
| JP2015503527A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2006506378A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2019529541A5 (enExample) | ||
| JP2019516707A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| KR101899613B1 (ko) | 염증 및 혈관 증식 관련 안 질환의 치료 방법 | |
| JP2021503010A5 (enExample) | ||
| RU2007106930A (ru) | Производные хиназолина | |
| JP2013503881A5 (enExample) | ||
| JP2007530703A5 (enExample) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| JP2019516726A5 (enExample) | ||
| JP2021503451A5 (enExample) | ||
| JP2017525684A5 (enExample) | ||
| JP2020527138A5 (enExample) | ||
| JP2019516722A5 (enExample) | ||
| JPH1036365A5 (enExample) | ||
| JP2018531961A5 (enExample) | ||
| JP2020536098A5 (enExample) |